Omega Pharma NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Omega Pharma NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH63149D
  • |
  • Pages: 31
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company's product portfolio includes cough and cold products, skin care products, pain relief products, vitamins, minerals, and nutritional supplements. Its products cater to gastro-intestinal disorders, respiratory issues, eye care, weight management, food supplements, baby care, and skin care. Besides, the company offers auto-diagnostic products such as body temperature meters, ovulation meters and blood pressure meters. It distributes these products to customers through retail distribution and drug store chains. Omega Pharma is headquartered in Nazareth, Belgium.

Omega Pharma NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 4

Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Omega Pharma NV, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 11

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 12

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 12

Partnerships 14

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 14

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 15

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 16

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 16

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 17

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 18

Licensing Agreements 18

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 18

Equity Offering 19

Omega Pharma Completes Public Offering Of Shares For US$237 Million 19

Debt Offering 20

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 20

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 21

Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 22

Acquisition 23

Perrigo Acquires Omega Pharma for USD4.76 Billion 23

Omega Pharma Acquires Naturoteek 25

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 25

Omega Pharma NV-Key Competitors 27

Key Employees 28

Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31

List of Figures

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Omega Pharma NV, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Omega Pharma NV, Deals By Therapy Area, 2011 to YTD 2017 8

Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 11

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 12

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 12

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 14

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 15

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 16

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 16

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 17

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 18

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 18

Omega Pharma Completes Public Offering Of Shares For US$237 Million 19

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 20

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 21

Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 22

Perrigo Acquires Omega Pharma for USD4.76 Billion 23

Omega Pharma Acquires Naturoteek 25

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 25

Omega Pharma NV, Key Competitors 27

Omega Pharma NV, Key Employees 28

Omega Pharma NV, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Omega Pharma NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com